Press Detail

PRESS RELEASE

Biotest AG reorganises stock exchange listing due to share split on 15 July 2015

- Share split at a ration of 1:3

- By share split and capital increase from company's funds the shareholder structure will not change

Dreieich, 8 July 2015. Biotest AG reorganises the stock exchange listing of its shares at a ratio of 1:3 due to the share split on 15 July 2015. Therefore the price per share is a third of its previous value because one share will be replaced by three shares. The share split was approved at the ordinary shareholders' meeting on 7 May 2015. Furthermore, a capital increase from the company's funds was approved so that every share carries a proportionate amount of the share capital of EUR 1.00. On 22 June 2015 the corresponding amendments to the articles of association were entered into the commercial register of the local court of Offenbach am Main.

On the evening of 14 July 2015, the stock of Biotest shares in the shareholders' account will be reorganised. For each previous ordinary share three ordinary shares and for each previous preference share three preference shares will be registered into the shareholders' accounts. By implementing the share split the existing shareholder structure does not change and there will be no dilution.

Biotest AG shares will continue to trade under ISIN DE0005227201 (ordinary shares) and ISIN DE0005227235 (preference shares).

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2,100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
email: investor_relations@biotest.de

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart